Ibogaine vs. Psilocybin: Which Psychedelic Treatment Is Right for You?

Ibogaine vs. Psilocybin: How They Compare for Addiction, PTSD, and Depression

Ibogaine and psilocybin — the active compound in what most people call magic mushrooms — are both gaining serious clinical attention as psychedelic medicines — but they are profoundly different compounds with different mechanisms, different risk profiles, and different conditions they treat most effectively. Choosing between them isn’t about which one is better. It’s about which one is right for your specific situation.

Quick Comparison Table

How Ibogaine Works

Ibogaine is an indole alkaloid derived from the root bark of Tabernanthe iboga. It acts at multiple receptor systems simultaneously: opioid receptor modulation (interrupting physical opioid dependence), NMDA receptor antagonism (rapid antidepressant effects), sigma-1 receptor agonism (neuroprotection, mood regulation), and critically, GDNF upregulation. Glial cell line-derived neurotrophic factor supports the survival of dopaminergic neurons damaged by chronic opioid and stimulant use — Dr. Dorit Ron at UCSF has published extensively on this mechanism.

Ibogaine is also metabolized to noribogaine, which has a 24–72 hour half-life and contributes significantly to ibogaine’s sustained effects in the days and weeks after treatment.

How Psilocybin Works

Psilocybin is a prodrug converted to psilocin in the body. Psilocin’s primary mechanism is agonism at 5-HT2A serotonin receptors, which are densely expressed in the prefrontal cortex. The most studied effect is disruption of the default mode network (DMN) — the brain regions associated with self-referential thinking and rumination that are hyperactive in depression and PTSD.

Dr. Robin Carhart-Harris at UCSF has published extensively on this mechanism using fMRI neuroimaging. Psilocybin also acts as a psychoplastogen (Dr. David Olson, UC Davis), promoting rapid structural plasticity in neurons and increasing dendritic spine density.

What Each Treats Best

Ibogaine’s strongest evidence: Opioid use disorder (the receptor mechanism is directly relevant), stimulant dependence (cocaine and methamphetamine, which have no FDA-approved pharmacological treatments), and traumatic brain injury. The landmark 2024 Stanford study in Nature Medicine (Dr. Nolan Williams et al.) found dramatic improvements in PTSD, alcohol misuse, and functional disability in veterans treated with ibogaine, including complete resolution of opioid withdrawal symptoms.

Psilocybin’s strongest evidence: Major depressive disorder (COMPASS Pathways Phase 2 trial, 233 patients, single 25mg dose produced significant reductions at 3 weeks), treatment-resistant depression (Dr. Carhart-Harris, Imperial College London, psilocybin vs. escitalopram), end-of-life distress (Johns Hopkins, NYU), and smoking cessation (Dr. Matthew Johnson, Johns Hopkins, 80% abstinence at 6 months).

Duration and Intensity

Ibogaine: 12 to 36 hours. The first phase involves intense visionary biographical memories. The second phase is a profound internal confrontation. The third phase can extend 6 to 12 more hours. Most patients do not sleep during this period. Nausea is common; the cardiovascular system is under pressure.

Psilocybin: 4 to 6 hours. The peak is typically 2 to 3 hours in. The experience can be deeply challenging but resolves within a manageable timeframe. The physical profile is relatively benign, with no significant cardiac risk.

Screening: The Critical Difference

The biggest practical difference between the two is how much medical process sits in front of treatment. Ibogaine requires a full work-up before you are accepted — an ECG, bloodwork and a line-by-line medication review — and that screening is where anyone who is not a safe candidate is identified and told so. Psilocybin’s work-up is far lighter. See our ibogaine safety guide for how the process runs end to end.

Psilocybin has no known lethal dose in humans. Cardiovascular effects are mild and transient. The primary risks are psychological: anxiety during sessions, and rare psychotic breaks in people predisposed to schizophrenia or bipolar disorder.

Someone with a cardiac history may not be a candidate for ibogaine while still being appropriate for psilocybin.

Legal Status

Ibogaine: Schedule I in the U.S., no legal domestic pathway. Available in Mexico, Jamaica, Netherlands, Costa Rica.

Psilocybin: Legal for therapeutic use in Oregon and Colorado. Also available in Jamaica, Netherlands, Costa Rica. Multiple Phase 2 and Phase 3 clinical trials ongoing with FDA Breakthrough Therapy designation for depression.

Cost

Ibogaine: $5,000–$15,000 for a complete programme, depending on length of stay and facility, plus travel. See what moves the price.

Psilocybin: clinical trials are typically provided at no charge to participants; Oregon licensed services $1,500–$3,500; international retreats $1,500–$5,000. Neither compound is covered by insurance.

Which Is Right for You?

Consider ibogaine if: Opioid dependence is your primary issue. You’ve failed multiple treatment attempts. You have a TBI history. You can pass full cardiac screening and travel internationally for 4–7 days.

Consider psilocybin if: Depression, treatment-resistant depression, or end-of-life distress is your primary concern. You want a legal domestic option (Oregon, Colorado). You have cardiac concerns that make ibogaine’s risk profile prohibitive. You prefer a shorter, less physically demanding experience.

Some patients benefit from both sequentially: ibogaine for addiction interruption, then psilocybin therapy later for underlying depression or trauma. We have guided people down both paths.

Can you do both?

Yes, sequentially — not together. The common pattern is ibogaine first to interrupt addiction, then psilocybin (or MDMA-assisted therapy) during the integration window to deepen the emotional work. They address different parts of the problem rather than competing.

Sequencing is a decision to make with the clinical team on both sides, and any current medication has to be reviewed before either.

How Psychedelic Connect Can Help

We hold every clinic we recommend to our published standard, before we will send anyone there. Our consultation starts with a real conversation about your history and which treatment pathway makes the most clinical sense. If psilocybin is the better fit, we’ll tell you that directly.

Call (866) 435-7057 or start your consultation online. Before any ibogaine consideration, read our ibogaine safety guide.

FAQ: Ibogaine vs. Psilocybin (Magic Mushrooms)

Q: Can you take ibogaine and psilocybin together?
A: Not simultaneously. Some practitioners sequence them — ibogaine first for addiction interruption, then psilocybin weeks or months later. Any sequencing requires medical oversight and adequate time between treatments.

Q: Which has more research behind it?
A: Psilocybin has a larger and more methodologically rigorous base, with multiple Phase 2 RCTs and FDA Breakthrough Therapy designation. Ibogaine’s evidence is compelling but relies more on observational studies. The 2024 Stanford study in Nature Medicine is a significant step forward for ibogaine research.

Q: Is ibogaine stronger than psilocybin?
A: In terms of intensity, duration, and physical demand, ibogaine is significantly more challenging. But “stronger” isn’t quite accurate — they’re different in kind. Psilocybin produces a more visual, expansive state; ibogaine produces an intense biographical confrontation.

Q: Can psilocybin treat opioid addiction?
A: Limited evidence so far. Psilocybin doesn’t directly address opioid receptors the way ibogaine does. It may help with underlying depression and psychological aspects of addiction, but it shouldn’t be expected to interrupt physical opioid dependence.

Q: What’s the biggest risk most people don’t know about?
A: Ibogaine: how much the choice of provider matters. The screening and monitoring around the medicine vary enormously between clinics, and that — not the compound — is what separates a safe programme from an unsafe one. Psilocybin: psychiatric risk in people predisposed to psychosis. Neither is unpredictable — both require proper medical screening.

Psychedelic Connect is a treatment advisory service. We do not provide medical advice. Ibogaine treatment involves serious medical considerations including cardiac risks. Always consult a qualified medical professional before pursuing any treatment.

For a full picture of what to expect, see what a program fee covers.

For where legal psilocybin is actually available, see psilocybin therapy centres.

Is ibogaine better than mushrooms for addiction?

For opioid dependence, the published evidence favours ibogaine — its best-documented effect is interrupting withdrawal, which psilocybin does not do. Psilocybin has the stronger trial evidence overall, but in different conditions: depression, end-of-life anxiety and alcohol use disorder. Neither question is settled, and the ibogaine work is mostly observational, with small numbers and no control group.

Are magic mushrooms safer than ibogaine?

On cardiac risk, yes — and that is the difference that decides who can be treated. Ibogaine affects heart rhythm, so clinics require an ECG, bloodwork and a full medication review, and some people are screened out entirely. Psilocybin has no comparable cardiac profile, though it carries its own risks around psychiatric history and medication interactions. “Safer” here means a wider pool of eligible people, not an absence of risk.

What is the difference between iboga and ibogaine?

Iboga is the plant; ibogaine is the principal alkaloid in its root bark. The preparation matters more than people expect — material sold as root bark has been measured anywhere from 0.6% to 11.2% ibogaine. See iboga vs ibogaine.